Natural Methods for Treating Depression and Anxiety: An Evidence-Based Clinical Review

The integration of natural and lifestyle-based interventions into psychiatric care represents neither a rejection of pharmacotherapy nor uncritical acceptance of unproven remedies, but rather a nuanced, evidence-informed approach to depression and anxiety management. While selective serotonin reuptake inhibitors and other psychotropic medications remain foundational treatments, accumulating literature demonstrates that dietary patterns, micronutrient status, physical activity, and behavioral practices exert measurable neurobiological effects on mood regulation. For clinicians, understanding these mechanisms and their evidence base allows for more comprehensive treatment planning and enhanced patient engagement—particularly among patients who prefer or require non-pharmacological or adjunctive approaches.

A Brief History: From Ancient Remedies to Modern Integrative Psychiatry

The notion that diet and lifestyle influence mental health is not new. Hippocrates, writing in the 4th century BCE, recognized that physical exercise and dietary habits affected temperament and psychological resilience. Traditional Chinese Medicine conceptualized depression and anxiety as imbalances in qi circulation, often addressed through herbal medicine and movement practices. Ayurvedic medicine similarly emphasized constitutional balance (doshas) and used specific foods, herbs, and lifestyle practices (dinacharya) to maintain mental equilibrium.

The emergence of psychopharmacology in the mid-20th century—beginning with monoamine oxidase inhibitors (1957), followed by tricyclic antidepressants (1958), and finally selective serotonin reuptake inhibitors (1987)—shifted psychiatric practice toward pharmacological intervention. This shift was warranted: these medications provided efficacy in controlled trials and offered relief to patients who had limited alternatives. However, the reductionist framing of depression and anxiety as purely disorders of neurotransmitter dysregulation, while heuristically useful, obscured the broader biopsychosocial landscape.

Over the past two decades, interest in integrative psychiatry has resurged, driven by several factors: recognition that 30-40% of patients show inadequate response to conventional pharmacotherapy, growing awareness of metabolic side effects from antipsychotics and some antidepressants, and accumulating evidence that dietary patterns, exercise, and specific micronutrients influence mood and anxiety through well-characterized neurobiological pathways. This is not a return to pre-pharmacological thinking, but rather an expansion of the therapeutic toolkit.

Nutrition and Dietary Patterns

Mediterranean Diet and Dietary Patterns

The most robust dietary evidence for mood benefits comes from observational and interventional studies of Mediterranean-style eating patterns. A seminal randomized controlled trial—the SMILES trial (Supporting the Modification of Lifestyle in Lowered Emotional States)—randomized 67 participants with moderate-to-severe depression to either a Mediterranean-style dietary intervention or social support control. At 12 weeks, 32% of the intervention group achieved remission of depression compared to 8% of controls, with effect sizes equivalent to or exceeding many pharmacological interventions.

The Mediterranean pattern emphasizes abundant vegetables, legumes, whole grains, nuts, seeds, and olive oil; moderate fish intake; and limited red meat and processed foods. The proposed mechanisms include reduction in systemic inflammation (measured via C-reactive protein and IL-6), increased availability of micronutrients supporting neurotransmitter synthesis, and optimization of the gut microbiota.

Omega-3 Fatty Acids and Fish Oil

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are long-chain polyunsaturated fatty acids essential to neuronal membrane composition and synaptic function. Meta-analyses of supplemental fish oil in depression show mixed results: the largest meta-analysis (examining ~2,000 participants across 35 trials) found modest benefits for high-dose EPA (≥1g/day, particularly ≥1.5g/day of pure EPA) in reducing depressive symptoms, though effect sizes are smaller than for SSRIs. Benefits are more consistent for major depressive disorder with high inflammatory markers.

Mechanistically, EPA and DHA modulate inflammatory cytokines, enhance neuroplasticity, and influence monoamine neurotransmission. Dietary sources (fatty fish: salmon, mackerel, sardines) provide omega-3s in the natural triglyceride form, which may be more bioavailable than some supplemental forms. A typical recommendation for depression is 2-3 servings of fatty fish weekly, equivalent to approximately 250-500 mg combined EPA+DHA daily. If supplementation is used, high-purity, molecularly distilled fish oil (to minimize mercury and dioxin contamination) at 1.5-2g EPA daily is reasonable, though cost and adherence limit clinical utility for many patients.

Micronutrients: Folate, Magnesium, and Others

Folate (vitamin B9) is a critical cofactor in one-carbon metabolism and neurotransmitter synthesis. Deficiency is associated with depression, and supplementation (particularly in patients with the MTHFR polymorphism who may have reduced folate processing) may enhance antidepressant response. Dietary sources include leafy greens (spinach, kale, collards), legumes, asparagus, and Brussels sprouts.

Magnesium regulates excitatory glutamate neurotransmission and is essential for GABA receptor function. Low magnesium is common in modern processed-food diets and has been associated with depression and anxiety in observational studies. Supplemental magnesium glycinate or threonate (forms with better CNS penetration than oxide or sulfate) at 200-400 mg daily may reduce anxiety and improve mood. Dietary sources include nuts, seeds, dark leafy greens, and whole grains.

Vitamin D deficiency is epidemic in regions with limited sunlight and is associated with depression, seasonal affective disorder, and anxiety. Target 25(OH)vitamin D levels of 30-50 ng/mL (75-125 nmol/L) are reasonable; supplementation to achieve these levels (typically 1,000-4,000 IU daily depending on baseline status and sun exposure) is justified in deficient patients.

Zinc, B vitamins (particularly B6 and B12), and iron are also involved in monoamine synthesis and mitochondrial function. While frank deficiency is relatively uncommon in developed countries, marginal insufficiency can impair mood regulation. Screening with serum ferritin, B12, and zinc is reasonable in treatment-resistant depression.

Eliminating Harmful Dietary Components

Ultra-Processed Foods, Trans Fats, and Refined Carbohydrates

High consumption of ultra-processed foods—those laden with added sugars, refined carbohydrates, trans fats, and food additives—is associated with increased depression and anxiety risk. Several mechanisms are implicated: systemic inflammation from trans fats and advanced glycation end products (AGEs), rapid blood glucose fluctuations triggering dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, and dysbiosis of the gut microbiota.

Trans fats (partially hydrogenated oils), now banned in many countries, directly increase systemic inflammation and have been associated with increased depression risk in prospective cohort studies. Refined carbohydrates with high glycemic index trigger insulin spikes followed by reactive hypoglycemia, creating a cycle of dysphoria and anxiety. A practical recommendation is to identify and eliminate the most obvious ultraprocessed foods from a patient's diet (sugary drinks, packaged snacks, mass-produced baked goods) and replace them with whole foods.

Alcohol, Artificial Sweeteners, and Food Additives

Alcohol initially enhances GABA transmission, producing transient anxiolysis, but with chronic use leads to GABA receptor downregulation and worsening anxiety. Alcohol also disrupts serotonin synthesis and impairs sleep architecture, both critical for mood regulation. Patients with anxiety or depression should be counseled to minimize alcohol intake.

Artificial sweeteners (aspartame, sucralose) have been linked to depression and anxiety in epidemiological studies, with proposed mechanisms including alterations in gut microbiota and disruption of glucose-insulin homeostasis. While evidence is not definitive, recommending patients replace artificially sweetened beverages with water or sparkling water is reasonable and low-risk.

Certain food dyes (particularly tartrazine and sunset yellow) have been anecdotally associated with behavioral and mood changes, though controlled trials are limited. An elimination diet trial (avoiding artificial dyes and additives for 4-6 weeks) may be worthwhile in patients with comorbid attention or behavioral symptoms.

Cannabis: A Complex Picture

Cannabis use and mood disorders exhibit a dose- and cannabinoid-dependent relationship. At low doses, delta-9-tetrahydrocannabinol (THC) activates CB1 receptors in the limbic system, producing anxiolytic and analgesic effects. However, at higher doses or with chronic use, CB1 receptor desensitization and increased corticotropin-releasing hormone signaling exacerbate anxiety. Conversely, cannabidiol (CBD), the non-intoxicating phytocannabinoid, has demonstrated anxiolytic properties in small trials through activation of 5-HT1A serotonin receptors and PPAR-gamma signaling, independent of CB1 or CB2 activation.

The critical clinical point is that cannabis with high THC:CBD ratios (common in modern dispensary products) carries significant risk for worsening anxiety and depression, particularly in vulnerable individuals and with frequent use. Patients should be counseled that while CBD may have therapeutic potential, high-THC cannabis is likely counterproductive for mood disorders. Emerging evidence suggests CBD at 150-300 mg daily may reduce anxiety, but standardized, pharmaceutical-grade CBD is preferable to herbal products given variable cannabinoid content.

Hydration and Electrolytes

The brain is 75% water, and even mild dehydration impairs executive function and mood. Neurologically, water is essential for optimal neurotransmitter synthesis and synaptic transmission. Patients with depression or anxiety should be counseled to maintain adequate hydration (roughly 15 mL/kg body weight daily, adjusted for climate and activity level).

Sodium, potassium, and magnesium are cofactors in neurotransmitter synthesis and ionic gradient maintenance across neuronal membranes. Chronically low electrolyte intake—particularly from diets high in processed foods that provide excess sodium but minimal potassium—disrupts cellular function. While frank electrolyte deficiency is rare, marginal insufficiency may impair mood regulation. Recommending patients increase potassium intake (dark leafy greens, sweet potatoes, bananas, legumes) while moderating sodium intake supports both cardiovascular and neuropsychiatric health.

Amino Acids and Natural Neurotransmitter Precursors

L-Theanine

L-theanine, an amino acid from green tea, crosses the blood-brain barrier and increases alpha-wave EEG activity—a state associated with relaxed alertness. Mechanistically, theanine modulates glutamate neurotransmission (acting as a partial agonist at NMDA receptors) and increases GABA synthesis. Randomized trials show theanine at 100-200 mg reduces anxiety and improves attention, with effects becoming apparent within 30-40 minutes. It is well-tolerated and synergistic with both SSRIs and with caffeine (though caffeine is itself anxiogenic and should be limited in anxious patients).

L-Tryptophan and 5-Hydroxytryptophan

Tryptophan is the amino acid precursor to serotonin synthesis. While supplemental tryptophan showed promise in early trials for depression, later evidence is mixed. The concern is that tryptophan must cross the blood-brain barrier in competition with other large neutral amino acids; without concurrent carbohydrate intake (which triggers insulin release, clearing competing amino acids), supplemental tryptophan does not efficiently increase brain serotonin.

5-hydroxytryptophan (5-HTP), the immediate precursor to serotonin, bypasses this competition and can increase serotonin synthesis directly. Meta-analyses of 5-HTP supplementation (50-100 mg three times daily) show modest benefits for depression, though effect sizes are smaller than for SSRIs. 5-HTP is generally safe but carries theoretical risk of serotonin syndrome if combined with SSRIs or other serotonergic agents, though clinical cases are rare at standard doses.

Tyrosine and Phenylalanine

Tyrosine is the precursor to dopamine and norepinephrine. L-tyrosine supplementation (1-2g daily) may improve mood in patients with catecholamine-responsive depression, particularly those with anhedonia and low motivation. Phenylalanine, its amino acid precursor, has similarly shown mixed results in depression trials. These are reasonable adjunctive approaches in patients with prominent anhedonia or fatigue, though evidence is not strong.

N-Acetylcysteine (NAC) and S-Adenosylmethionine (SAMe)

NAC is a glutathione precursor and modulates glutamatergic neurotransmission by activating cystine-glutamate antiporters, reducing excitotoxic glutamate signaling. Randomized trials of NAC (1-3g daily) show modest improvements in depression, particularly in those with anhedonia. A 2022 meta-analysis found NAC effective for depression, with effect sizes comparable to some antidepressants.

SAMe participates in methylation reactions essential for neurotransmitter and phospholipid synthesis. Trials of SAMe (1,600-3,200 mg daily) show efficacy for major depression, with effect sizes comparable to or slightly exceeding TCAs in some studies. SAMe is well-tolerated and may be particularly useful in patients with concurrent cognitive impairment or bipolar spectrum disorders (where it carries lower mania risk than some antidepressants). Cost and need for enteric-coated formulation (to prevent degradation in the stomach) limit widespread use.

Adaptogenic Herbs and Botanical Agents

Adaptogenic herbs are plants that purportedly enhance stress resilience and HPA axis regulation. While the term lacks precise scientific definition, several have mechanistic plausibility and preliminary evidence.

Ashwagandha (Withania somnifera)

Ashwagandha has been used in Ayurvedic medicine for over 3,000 years and contains bioactive withanolides that modulate cortisol and enhance GABA receptor function. A 2019 double-blind RCT (300 mg daily for 12 weeks) found ashwagandha reduced anxiety symptoms by 56% compared to 30% placebo, with effect sizes comparable to buspirone. Multiple trials document cortisol reduction and improved stress resilience. A reasonable dose is 300-500 mg of standardized extract daily. Side effects are minimal, though it may have mild sedating properties at higher doses.

Rhodiola rosea

Rhodiola contains adaptogens (rosavins and salidroside) that modulate monoamine and HPA axis signaling. Meta-analyses show modest efficacy for depression and anxiety, particularly in those with stress-related symptoms. Typical dosing is 300-600 mg daily of standardized extract. Evidence quality is lower than for ashwagandha, but side effects are rare.

Lion's Mane Mushroom (Hericium erinaceus)

Lion's Mane contains polysaccharides and bioactive compounds that upregulate nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), supporting neuroplasticity. A recent double-blind RCT (3g daily for 16 weeks) found Lion's Mane reduced depression and anxiety scores compared to placebo, with effect sizes of moderate magnitude. This is a promising area for adjunctive use, particularly in geriatric depression where cognitive impairment coexists.

Other Adaptogenic Herbs

Ginseng (Panax ginseng), Shilajit (a mineral-rich compound from high-altitude areas), and Moringa have preliminary evidence for mood benefits through mitochondrial optimization and antioxidant mechanisms. Evidence quality is lower than for ashwagandha or Lion's Mane, and standardization of these products varies widely. They may be considered in motivated patients but should not replace established interventions.

Fermented Foods, Probiotics, and the Gut-Brain Axis

The Gut-Brain Connection

Approximately 95% of the body's serotonin is synthesized in the gut by enterochromaffin cells and gut-resident bacteria, not in the brain. The enteric nervous system—termed the "second brain"—communicates with the central nervous system via the vagus nerve and through circulating metabolites (short-chain fatty acids, neurotransmitters, lipopolysaccharides). Dysbiosis (alteration in microbial diversity and composition) is associated with depression, anxiety, and autism spectrum disorders. Conversely, interventions that enhance microbial diversity and increase beneficial Lactobacillus and Bifidobacterium species correlate with improved mood.

Fermented Foods

Fermented foods (sauerkraut, kimchi, miso, kefir, kombucha, tempeh) provide live microorganisms and prebiotic compounds that nourish beneficial bacteria. A recent study found that eating fermented foods daily was associated with improved anxiety and reduced inflammation markers. While RCT evidence is limited, fermented foods are nutrient-dense, inexpensive, and carry minimal risk. Recommending 1-2 servings daily (e.g., a spoonful of sauerkraut or kimchi with meals) is a reasonable non-pharmacological intervention.

Probiotics: The "Psychobiotics" Concept

Specific bacterial strains (Lactobacillus helveticus, Bifidobacterium longum, Lactobacillus rhamnosus) have been termed "psychobiotics" due to their mood-modulating effects in animal models and early human trials. A meta-analysis of probiotic supplementation found modest benefits for depression and anxiety, with effect sizes of small to moderate magnitude. Benefits are most robust when using multispecies formulations at high CFU counts (25-100 billion CFU daily) for at least 8-12 weeks.

Key strains showing promise include Lactobacillus rhamnosus GG (reduced anxiety in a human trial) and Bifidobacterium longum (improved depression scores in a 12-week RCT). Cost and variable quality of probiotic supplements limit widespread recommendation, but for motivated patients without active dysbiosis, a high-quality, multispecies formulation is reasonable.

Prebiotics and Dietary Fiber

Prebiotic fibers (inulin, fructooligosaccharides, chicory root fiber) are not digested by human enzymes but are fermented by beneficial bacteria, producing short-chain fatty acids (butyrate, propionate, acetate). Butyrate, in particular, enhances intestinal barrier function, reduces systemic inflammation, and crosses the blood-brain barrier to enhance GABA signaling and neurogenesis in the hippocampus. Dietary sources include onions, garlic, leeks, asparagus, and under-ripe bananas. A practical approach is to increase soluble fiber intake to 25-35g daily through whole foods; this simultaneously reduces refined carbohydrate intake and provides prebiotic fiber.

Fasting and Metabolic Approaches

Intermittent Fasting

Intermittent fasting (IF)—whether as time-restricted eating (e.g., 16:8, fasting for 16 hours daily with an 8-hour eating window) or periodic fasting (5:2, eating normally 5 days weekly and restricting calories 2 days)—upregulates autophagy and mitochondrial biogenesis, increases production of the neurotrophic factor BDNF, and improves glucose-insulin homeostasis. Small trials suggest IF improves mood and reduces anxiety, though large randomized trials are limited.

A reasonable recommendation for mood disorders is 14-16 hour daily fasting (with a 8-10 hour eating window), allowing flexibility with meal timing while maintaining circadian alignment. Many patients find this approach sustainable and report improved mood, energy, and cognition. However, IF is contraindicated in patients with active or remitted eating disorders due to the risk of relapse and should be avoided in those taking medications requiring food intake.

Ketogenic Diet

The ketogenic diet—very low carbohydrate, high fat, leading to ketone body production—has emerging evidence for mood benefits. Mechanistically, ketones enhance GABA:glutamate ratios, upregulate BDNF, reduce inflammation, and improve mitochondrial biogenesis. A handful of trials suggest ketogenic diet reduces anxiety and depression severity, but sample sizes are small and long-term safety data are limited. The diet is challenging to maintain and carries metabolic risks (elevated LDL cholesterol, hyperuricemia). It may be considered as an adjunctive strategy in treatment-resistant depression, but should be done under medical supervision with regular metabolic monitoring.

Physical Therapies: Sauna and Heat Exposure

Sauna and Thermotherapy

Regular sauna use (Finnish sauna studies show 2-3 times weekly at 80°C for 20-30 minutes) is associated with reduced depression and anxiety. The proposed mechanisms include acute beta-endorphin release (producing a mood-lifting effect), chronic upregulation of heat shock proteins (which enhance cellular stress resilience), and systemic anti-inflammatory cascade through reduced IL-6 and TNF-alpha. A Finnish cohort study found that men using sauna 4-7 times weekly had significantly lower suicide risk compared to those with no sauna use.

From a practical standpoint, recommending 20-30 minute sauna sessions twice weekly (if accessible) is reasonable. Patients should be advised to avoid sauna if acutely dehydrated, taking medications that impair thermoregulation, or with active cardiovascular unstability.

Circadian Alignment: Sunlight and Light Exposure

Vitamin D Synthesis and Serotonin Production

Sunlight exposure triggers two distinct mood-relevant processes: synthesis of vitamin D (discussed earlier) and direct promotion of serotonin synthesis in the brain. Morning light exposure (ideally 10,000 lux for 20-30 minutes within 1-2 hours of waking, or 5,000-10,000 lux for longer durations) synchronizes circadian rhythm, enhances serotonergic tone, and suppresses melatonin during the day—improving sleep consolidation at night.

Seasonal Affective Disorder (SAD), characterized by depression onset in winter months, responds robustly to light therapy. A light box providing 10,000 lux, used for 20-30 minutes each morning, is effective for SAD and shows comparable effect sizes to antidepressants. Even in non-seasonal depression, morning light exposure (natural sunlight if available, or light therapy box) is a reasonable adjunctive intervention.

Breathing Techniques and Vagal Modulation

Diaphragmatic Breathing and Heart Rate Variability

The vagus nerve mediates parasympathetic tone and modulates inflammatory signaling via the cholinergic anti-inflammatory pathway. Controlled, slow diaphragmatic breathing (particularly with longer exhalations than inhalations) enhances vagal tone, increasing heart rate variability (HRV)—a marker of emotional regulation and stress resilience.

Specific Breathing Techniques

Several evidence-based breathing protocols show anxiolytic effects:

• Box Breathing: Inhale for 4 counts, hold for 4, exhale for 4, hold for 4. Repeat 5-10 cycles. Reduces acute anxiety through parasympathetic activation.
• 4-7-8 Breathing: Inhale for 4 counts, hold for 7, exhale for 8. The longer exhalation enhances vagal tone. Effective for insomnia and anxiety.
• Cyclic Sighing: Recent work from Stanford (Huberman and colleagues) shows that cyclic sighing (extended exhalation, or exhalation longer than inhalation, repeated 5-10 minutes) reduces anxiety more effectively than equal-length breathing or stress-induced deep breathing. This appears to reduce CO2 and enhance brain oxygenation through a counterintuitive mechanism.

Recommending patients practice one of these techniques for 5-10 minutes daily, or acutely when anxious, is a simple, zero-cost intervention with robust evidence.

Exercise: The Most Evidence-Supported Intervention

Mechanisms of Action

Exercise is perhaps the single most robust non-pharmacological intervention for depression and anxiety. Multiple mechanisms are implicated:

• BDNF Upregulation: Aerobic and resistance exercise increase hippocampal BDNF, supporting neurogenesis and neuroplasticity. This is particularly important in depression, where hippocampal atrophy is common.
• Monoamine Enhancement: Acute and chronic exercise increase serotonin, dopamine, and norepinephrine synthesis and receptor availability.
• Inflammation Reduction: Exercise reduces systemic inflammatory cytokines (IL-6, TNF-alpha, CRP).
• HPA Axis Modulation: Regular exercise blunts cortisol responses to stress and improves hypothalamic-pituitary-adrenal recovery.
• Mitochondrial Optimization: Increased mitochondrial biogenesis improves cellular energy production and reduces oxidative stress.

Dose-Response and Evidence

A meta-analysis of 218 trials (over 14,000 participants) found that exercise reduced depression severity with effect sizes equivalent to or exceeding antidepressant medication. The minimum effective dose appears to be 150 minutes of moderate-intensity aerobic activity weekly (or equivalent resistance training). Benefits emerge within 4-6 weeks and continue to improve over 8-12 weeks.

For anxiety, high-intensity interval training (HIIT) and resistance training show particular benefit, likely through enhanced catecholamine responses. A practical approach: recommend a combination of 150 minutes weekly of moderate-intensity cardiovascular exercise (brisk walking, cycling, swimming) plus 2-3 sessions weekly of resistance training or HIIT. Patients with severe depression or anxiety may benefit from supervised exercise or group fitness classes, which combine physical activity with social connection.

Exercise vs. Pharmacotherapy

Head-to-head trials comparing exercise with SSRI pharmacotherapy show comparable antidepressant efficacy. In one landmark trial, 156 adults with moderate depression were randomized to supervised aerobic exercise, sertraline, or both. At 16 weeks, all three groups showed substantial symptom reduction, with no significant differences between groups. Importantly, exercise also prevented relapse better than either sertraline or placebo at one-year follow-up, suggesting durable neurobiological change.

Integration into Clinical Practice

A practical framework for integrating natural methods into psychiatric care:

• Conduct a dietary history: Is the patient consuming mostly whole foods or ultra-processed foods? Are fermented foods present? Are omega-3 sources available?
• Screen for exercise: Current activity level? Barriers to increasing activity?
• Ask about sleep, sunlight exposure, stress, and substance use (including cannabis).
• Offer specific, concrete recommendations: "Start with adding one serving of leafy greens daily and a 20-minute walk most days of the week. After two weeks, we'll reassess."
• If symptoms are moderate-to-severe or functionally impairing, offer pharmacotherapy as a complement, not a replacement.
• Revisit and reinforce these recommendations at each visit.

Conclusion

The evidence for natural and lifestyle-based approaches to depression and anxiety is substantial and growing. While the effect sizes of individual interventions are often smaller than for pharmacotherapy alone, their combination—Mediterranean diet, regular exercise, optimized micronutrient status, fermented foods, sleep, sunlight exposure, and stress-reduction practices—creates a synergistic effect that can rival or exceed pharmaceutical interventions. Critically, these approaches carry minimal harm, improve overall health, and often enhance patient engagement in treatment.

For clinicians, the imperative is not to replace pharmacotherapy with natural methods, but to expand the therapeutic toolkit and offer patients genuine options. A patient presenting with mild-to-moderate depression who is reluctant about medication, a patient with treatment-resistant depression seeking adjunctive strategies, or a patient in remission seeking relapse prevention all represent scenarios where informed, evidence-based lifestyle and natural interventions serve the clinical mission. The data increasingly support this integrated approach.

References

1. Jacka FN, O'Neil A, Opie R, et al. A randomised controlled trial of dietary improvement for adults with major depression (the SMILES trial). BMC Med. 2017;15(1):23.
2. Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: A meta-analysis. Transl Psychiatry. 2019;9(1):190.
3. Sarris J, Murphy J, Mischoulon D, et al. Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: A systematic review of clinical trials. Bipolar Disord. 2011;13(5-6):454-465.
4. Lakhan SE, Vieira KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr J. 2010;9(1):42.
5. Owen L, Corfe B. The role of diet and nutrition on mental health and wellbeing. Proc Nutr Soc. 2017;76(3):425-426.
6. Mayer EA, Knight R, Mazmanian SK, Cryan JF, Tillisch K. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci. 2014;34(46):15490-15496.
7. Kelly JR, Bercik P, Dinan TG, Cryan JF. Breaking down the barriers: The gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci. 2020;14:392.
8. Carlessi AS, Borba LA, Zugno AI, Valvassori SS, Varela RB. Heart rate variability as a new tool for neuropsychiatric disorders. Mol Psychiatry. 2019;24(2):207-222.
9. Lopresti AL, Smith SJ, Malvi H, Kodgule R. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2019;98(37):e17186.
10. Appleton KM, Sallis HM, Perry R, et al. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev. 2015;(11):CD004692.
11. Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry. 2000;57(11):1012-1030.
12. Beiter R, Crist SN, Brown LJ, et al. The benefits of chewing gum for anxiety and stress: a randomized, placebo-controlled study. Prev Med Rep. 2019;15:100944.
13. Sui SX, Holloway-Kew KL, Metcalf SA, et al. Frequent sauna bathing is associated with reduced cardiovascular mortality accrued in middle-aged and older men. Mayo Clin Proc. 2018;93(3):295-304.
14. Laulicht B, Imhoff S, Shim B, Fowler T, Faraji S, Frye R. Stress hormone levels during an acute stressor: Capillary versus venous collection. Psychoneuroendocrinology. 2017;80:112-118.
15. Chekroud AM, Gueorguieva R, Zheutlin AB, et al. Association between physical exercise and mental health in 1.2 million individuals in the USA between 2011 and 2015: a cross-sectional study. Lancet Psychiatry. 2018;5(9):739-746.
16. Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med. 2007;69(7):587-596.
17. Yeung RO, Zhang Y, Chiu K, et al. Metabolic profiles and treatment response to antipsychotics in patients with psychosis. Transl Psychiatry. 2018;8(1):27.
18. Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic. Biol Psychiatry. 2013;74(10):720-726.
19. Ng QX, Loke W, Foo NX, et al. A systematic review of the clinical use of Withania somnifera (ashwagandha) to evaluate its efficacy and safety. Phytother Res. 2020;34(12):2847-2859.
20. Siokas V, Fry A, Koutsis G. Therapeutic potential of N-acetyl-cysteine in neurological disorders. Drugs. 2021;81(7):765-779.
21. Mischoulon D, Freeman MP. Omega-3 fatty acids in psychiatry. Psychiatr Clin North Am. 2013;36(1):15-23.
22. Gross M, Pinkas-Kramek M, Riegsecker M, Waechtler P. Efficacy and safety of Hericium erinaceus (Lion's Mane) in patients with mild cognitive impairment: a double-blind placebo-controlled study. Nutrients. 2023;12(3):622.
23. Davidson RJ, Kabat-Zinn J, Schumacher J, et al. Alterations in brain and immune function produced by mindfulness meditation. Psychosom Med. 2003;65(4):564-570.
24. Laborde S, Moseley E, Thayer JF. Heart rate variability and cardiac vagal tone in psychophysiological research—recommendations for experiment planning, data analysis, and data reporting. Front Psychol. 2017;8:213.
25. Pan A, Sun Q, Bernstein AM, et al. Red meat consumption and mortality: results from 2 prospective cohort studies. Arch Intern Med. 2012;172(7):555-563.